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Abstract
Stroke, a disease of millions, and a financial burden for many more is still challenging
health sciences, as we greatly increase our efforts to better understand stroke patho‐
genesis, early diagnose, prevent and treat high risk and major risk factors we still need
to update our clinical and surgical skills in treating stroke event and its aftermath. Use
of applied anatomical and physiological knowledge should apply the same everywhere,
and based on these standard principles we should be able to predict the early course of
stroke neuropathology and its  potential  consequences.  Updated new guidelines of
recombinant  tissue  plasminogen  activator  (r‐tPA)  indications  should  help  in  early
intervention when correct diagnosis is promptly made, but as the list of contraindica‐
tions as well has changed staff neuroscientists should consider all possible medical and
or surgical options for treatment. With prompt actions to try to reinstate perfusion we
should always try to do so within the first 4 h, and having a maximal additional 2 h in
reserve to consider surgical therapeutic options (should the clinic/unit’s infrastructure
allow it). Treatment modalities, therapeutic/endovascular and or surgical (embolecto‐
my, bypass, decompression) are the alternatives among which we should wisely chose
to treat our patients based on the best medical practice not in the skills of the individuals
performing each or either procedure. It is of critical importance to know when surgery
should be performed, how to calculate craniotomy size, what are the intra‐, extra‐cranial
surgical landmarks and when should we put the bone back in cases of decompression.
We should be able to correctly predict at what extent volume and intracranial pressure
values will  change by the size of decompressive craniectomy and its  effect on the
patient’s prognosis. Clinic is the best indicator for timing of surgical decompression as
it is the sole determinant of any other treatment option, and what high risk and major
risk factors are present (if any) at the time of diagnosis will predict the clinical outcome
of the patient, but not the age (which should not be the limit).
Keywords: Cerebrovascular Anatomy, Neuropathology, Clinics of Stroke, Embolecto‐
my, Vascular Bypass, Decompression Techniques
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1. Stroke syndrome, preamble
In this chapter, we try to explain through principles of anatomy, physiology, and hemody‐
namics of fluids how does it happen and why these are the series of pathological events
following a cerebrovascular occlusion. What can we do differently to treat stroke syndrome?
The main focus is on the invasive modalities of the treatment of stroke syndrome, specifically
endovascular and surgical techniques.
Is it the best possible way to treat stroke syndrome itself by preventing and treating all
the disease processes that risk and cause stroke syndrome?
2. Epidemiology, facts, stroke
Some of the facts of stroke syndrome are as follows:
1. Major neurological disease of our times
2. Second leading cause of death worldwide
3. Second largest contributor to hospital care cost among cardiovascular diseases
4. The leading cause of serious long‐term disability
5. Its risk varies by race, ethnicity, and age and geography.
According to World Health Organization (WHO), 15 million people suffer stroke worldwide
annually, and of these
1. 5 million die, 5 million are permanently disabled;
2. Stroke can and do occur at any age;
3. Hypertension contributes to more than 12.7 million strokes worldwide;
4. Atrial fibrillation is an independent risk factor for stroke, increasing risk by fivefold;
5. Incidence is 1.5/1000/year and rising rapidly with age to 10/1000/year at 75 years;
6. Male/female ratio of >1:1 (male>female);
7. Life‐threatening complete middle cerebral artery (MCA) infarction—up to 10%, with
mortality from malignant infarction—up to 80%;
Early action is important, the chances of survival are greater when treatment begins quick‐
ly (within 3 h cutoff), and these patients tend to have less disability 3 months after stroke
[1].
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3. Brain anatomy, physiology, facts
At any moment in normal conditions (Monro-Kellie equation):
= + +Intracranial space Brain Blood CSFVolume Vol Vol Vol (1)
Average human brain of an adult,
weight
1300–1400 g [2]
– Comprising 80% of brain weight
Hemisphere of an adult, weight 400 g
– 55% of blood supplied by MCA
– 25% supplied by ACA
– 15% supplied by PCA
– 5% supplied by anastomotic branches
Average weight of an adult cerebellum 150 g
Inside skull volume ≈1600 ml
– 80% made by brain tissue
– 20%
– 55% CSF
– 45% blood
– <5% (60–80 ml) virtual space between cranial bone, meningeal layers,
and brain
Cerebral blood flow (CBF) 750 ml/min (≈20% cardiac output)
50 ml/100 g/min
Changes in intracranial volume before:
– Clinical signs appear
– Imagery signs appear
– ≥60 ml
– ≥80 ml
Volume of adult human brain 1200 cm3
– 1100 cm3 female
– 1200 cm3 male
Cerebrospinal fluid (CSF) volume, adult 150–270 ml
– 25 ml, volume of ventricles
CSF production rate 0.2–0.7 ml/min
600–700 ml/day
Cerebral metabolic rate of O₂
consumption (CMRO₂)
3–4 ml/100 g tissue/min
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Average human brain of an adult,
weight
1300–1400 g [2]
– Comprising 80% of brain weight
Normal intracranial pressure (ICP) 5–15 mmHg
– 1–5 mmHg, infants
– 5–10 mmHg, children
– 5–15 mmHg, adolescents, adults
Critically raised ICP ≥20 mmHg
Table 1. Brain anatomy, physiology, facts.
CBF = CPPCVR = MAP − ICPCVR
The only parameters in which we have some medical and or surgical control (however, with extreme limitations).
Constantly changing variables
CBF, cerebral blood flow Yes
CPP, cerebral perfusion pressure Yes
CVR, cerebrovascular resistance Yes
MAP, mean arterial pressure No, within a wide normal range
ICP, intracranial pressure Yes, but has a very narrow range
Main factors influencing cerebral blood flow circulation are as follows:
– Systemic blood pressure (BP)
– The arterial blood gas levels
In the range of 60–140 mmHg, systemic BP has minimal effect on the CBF, due to autoregulation (via cerebral blood vessel
dilation and contraction). MAP has the widest range of autoregulation.
↑ in BP ≥ 150 mmHg  ↑ CBF, ↑ ICP
↓ in BP ≤ 50 mmHg  ↓ CBF, and can potentially cause cerebral ischemia.
Hypercapnic vasodilation:
PaCO₂, the most important regulator.
Control—central chemoreceptors, medulla, brain stem.
Except in patients with medullary damage, or long‐standing COPD (chronic obstructive pulmonary disease), when PaO₂
levels become a significant contributor to the respiratory drive.
Hypoxic vasodilation:
PaO₂ has a less profound effect, only when
PaO₂ ↓ ≤ 50 mmHg  ↑cerebral perfusion.
Control—peripheral chemoreceptors, carotid and aortic bodies.
Table 2. Determinants of cerebral blood flow.
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All three variables, components in this equation, are inversely related in normal autoregula‐
tion. Changes in the increase of at least one of the variables that are not accompanied with
inverse relations of the other variables will results in ↑ intracranial volume and pressure (↑
ICP) eventually.
For these mathematical reasons that any increase in the intracranial volume up to 60 ml can
be accommodated first by spinal movements of cerebrospinal fluid (CSF) before clinical (>60
ml ↑ in volume) and radiological (>80 ml ↑ in volume) signs of herniation occur (Table 1).
In their review, Schaller et al. revoked the classical equation of Kellie‐Monro and suggested a
more differentiated description for the dynamic of ICP, and its relation to cerebral blood flow
(CBF). Several experimental and clinical studies have given evidence that this equation and
the consideration of the intracranial volume to be a closed system are not entirely true from
the physiological and pathophysiological point of view; even so the understanding of this
phenomenon is incomplete [3].
CBF and blood pressure have a direct relation, and the main determinants of CBF are mean
arterial pressure (MAP) and cerebrovascular resistance (CVR) (Table 2) (Graphic 1).
Graphic 1. Determinants of cerebral blood flow, correlation.
The arterial blood gases have a more powerful effect on the CBF. The medullary respiratory
center controls the depth and the rate of respiration based on input from
– Chemoreceptors, located at
– Centrally, brain stem;
– Peripherally.
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– Airway mechanoreceptors, regulate the duration of inspiration (Hering‐Breuer reflex).
Cerebrovascular resistance (CVR) is affected by changes in
– PaCO₂;
– CPP (cerebral perfusion pressure).
The ratio, CBFCMRO2 , is 14–18 (coupling ratio), when the brain is at the point of lowest O₂ con‐
sumption/g tissue.
For every region of cortex activated, the required ↑ of CBF by ≈ 30% will require a minimum
↑ of cerebral metabolic rate of oxygen consumption (CMRO₂) by ≈ 5% [4] (Graphic 2).
Graphic 2. Cerebral blood flow‐O₂ utilization correlation.
Brain‐tissue oxygen extraction exceeds that of any other tissue/organ (except for myocardial
tissue); therefore, ↑ in the brain O₂ demand are met by a nearly proportional ↑ in vascular blood
flow.
We can assume that by reducing the metabolic rate of the brain tissue, we may try and reach
lower levels of oxygen consumptions during disease processes. The steps that can be taken to
manipulate to some degree and reduce the CMRO₂ are by
1. Reducing the electrical activity of neurons (e.g., the use of barbiturates, general anesthe‐
sia);
2. Reducing the maintenance energy of neurons (e.g., hypothermia);
‐ Deep hypothermia (≈20°C) permits the brain to tolerate up to 1 h of circulatory arrest
(more data required).
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4. Cerebrovascular anatomy
We will use stroke imagery, and demonstrate simultaneously patent and occluded vessel as
they mirror in the Circle of Willis, labeling the vessels most often affected (of particular interest
for this chapter) in the stroke syndrome (Figure 1). A computerized tomography (CT) scan
without contrast is the first diagnostic imagery, followed when possible by angio/angio‐CT/
magnetic resonance imaging (MRI) scan. Angiography has its superiority in stroke syndrome
as the diagnostic standard following the CT scan when possible; it can lead the way to
endovascular procedures, should the infrastructure of the clinics support it [5, 6]. Successful
endovascular treatment of the occluded vessel can save life. Limitations in the use of endo‐
vascular treatment exist in many clinics; they rely mostly on medical treatment options and
surgical bypass and or decompression modalities for their patients.
Figure 1. Imagery findings during stroke event, anatomical correlations. 1. A CT scan without contrast, illustrating
main hemispheric cerebrovascular territories and ischemic zone under pathological progression in the MCA territory.
2. Anteroposterior view. 3. Lateral view, early diagnostic angiography images, demonstrating patent and occluded ves‐
sels. 4. Angio‐MRI of Circle of Willis, mirroring the patent and occluded vessel after an acute ischemic accident.
Following internal carotid artery (ICA), MCA is the largest vessel in the anterior circulation.
It supplies the largest brain‐tissue territory, and it is for this anatomical reason that its occlusion
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is “malignant.” Of its two branches (superior and inferior), occlusion of the superior has a
devastating clinical course, if not the main MCA, and it supplies almost 60% of the main
territory of the MCA main:
– There is considerable variability of the major arteries, and the central distribution [7];
– A balanced configuration of the Circle of Willis is present in only 18% of the population;
– Hypoplasia of one or both posterior communicating (P‐comm) occurs in 22–32%;
– Absent or hypoplastic A1 segments occurs in 25%;
– 15–35% of patients supply their posterior cerebral artery on one or both sides from the
carotid (via P‐comm) instead of via the vertebrobasilar system (fetal circulation);
– Large arteries are the primary conduit for blood delivery to the tissues, and contain a large
amount of smooth muscle in their walls to regulate blood pressure and withstand high
pressure/stress;
– Small arteries and arterioles are the primary site of hormonal regulation of systemic blood
pressure and the primary vascular site of vasoactive anti‐HTN (hypertension) drugs such
as Ca2+ channel blockers or alpha‐adrenergic blockers.
5. Biophysics of fluids and flow hemodynamics in normal vasculature
Cerebral blood flow is supplied by vessels connected in series and in parallel (Figure 4).
For each individual vessel, the law of the conservation of mass applied to the steady state of
an incompressible fluid through a system of cylinders of varying cross‐sectional areas tells us
that
( ) ( ) constant= ´ =Total flow flow velocity V cross sectional area A (2)
This principle may be applied to blood flow in the cerebrovascular system. The law of
conservation of mass as applied to fluid dynamics tells us that the total flow of mass into a
contained system (before any vessel is damaged) must be equal to the total outflow of mass
from the system steady state (Figure 3).
Applying this principle:
Flow/Qin = grams of fluid material in/unit time = volume in × density (in)/time;
Flow/Qout = grams of fluid material out/unit time = volume out × density (out)/time.
For a relatively incompressible fluid (e.g., blood), density may be considered constant;
therefore, in a steady state,
Volume in (Vol in) = Volume out (Vol out)
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Vol in = A1 × V1 = Vol out = A2 × V2
Figure 2. Biophysics of fluids and hemodynamic in normal vasculature.
Figure 3. Relation of section area with flow velocity, in a steady state.
Figure 4. The most common sites of atherosclerotic events in the Circle of Willis. r1—vessel radius proximal to bifurca‐
tion. r2, r3—vessel radius distal to bifurcation.
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In a steady state, the flow at a given point is directly proportional/related to the cross‐sectional
(A) area at that point (Figure 2) (Table 3). This explains why immediate distal to bifurcation,
wall tension is higher/greater than proximal. This principle of hemodynamics of fluids in
cylinders explains the reason of increased frequency of vascular‐wall changes (atherosclerosis)
at points of narrowing and or curvatures (red arrows), in the Circle of Willis (Figure 4). The
same principles are used in Doppler echographic measurements.
Re = ���� � = �1 − �2�� × �4 Constantly changing variables
Re, Reynolds number No
ρ, density of the liquid No, it has a very narrow range
ω, flow velocity of the liquid Yes
d, orifice/vessel diameter Yes
r, radius of the vessel Yes
ɳ, viscosity Yes, but to a narrow range
L, length of the blood vessel No
∆P, pressure gradient between two points in the vessel Yes
R, resistance to flow in the vessel Yes
A small change in blood vessel radius can have a profound effect on the flow through a vessel; it is based on these
simple principles of hemodynamics that we can explain the changes in the flow and pressure when larger vessels
bifurcate to smaller ones (Figures 3 and 4).
Table 3. Variables in the Reynolds equation and Poiseuille’s law/equation.
Figure 5. Biophysics of occlusive cerebrovascular disease pathology.
Note: although individual capillaries have a small cross‐sectional area, the flow velocity
through these vessels is slow. This is because numerous capillaries arranged in parallel receive
flow from a given feeder vessel; thus, the functional cross‐sectional area combined is actually
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much larger than that of the feeder vessel from which they receive their flow. Applying this
principle, we can explain why:
Blocking of one of the vessels in parallel in this system (e.g., thrombus)  ↑ pressure and flow
in the rest of the system
This is due to the fact that the resistance to flow in a blood vessel is inversely proportional to
the radius raised to the fourth power (Figure 2).
Diagram 1. Stroke‐event progression.
Figure 6. Reactive gliosis and glial scar formation. Cleaning of debris starts from the periphery (where possible anasto‐
moses supply the area with blood and metabolites first, this is the route for neutrophils and macrophages to arrive and
signal for more astrocytes stimulation/activation) to the center. 1. Non‐contrast CT scan, second week of stroke event.
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Reactive gliosis and vascular proliferation around the necrotic area are indicated. 2. Non‐contrast CT scan, third week
of stroke event.
The cerebral metabolic rate of oxygen consumption arises from neurons utilizing energy for
two functions:
1. Maintenance of cell integrity, cell homeostasis, which normally accounts for ≈40% of
energy consumption;
2. Conduction of electrical impulses (neuronal work, ≈ 60%).
Oxidative phosphorylation produces ≈99.99% of energy/adenosine triphosphate (ATP).
Anaerobic phosphorylation produces only ≈0.01% of energy required for utilization by
neurons. In an event of stroke, it is the 0.01% time‐energy during which we depend to try and
reverse hypoxia and/or treat stroke and its consequences (Figure 5) (Diagram 1).
6. Neuropathology of occlusive cerebrovascular disease
– Probably/regardless of proper treatment, the transudate of edema proximal to vascular
occlusion tends to resolve (Figure 5). But our patient’s progressive clinical and patholog‐
ical deterioration suggests a less reversible exudation process (Table 4).
Time from
injury/event
Microscopic changes Macroscopic changes (Figure 7)
12–24 h “Red neurons” eosinophilic cytoplasm, pyknotic nuclei, loss of
Nissl substance.
Sings of irreversible damage, from this moment onward.
First changes appear that can be seen
macroscopically as well.
At any time, the patient is at risk for
extracranial complication and
superimposed conditions.
24–72 h Neutrophils infiltrate the area after the interruption of blood
supply; they do not phagocytize myelin remnants.
3–7 days Macrophage/microglia infiltration and phagocytosis begin.
Neutrophils continue moving into the area, followed by
microglia.
1–2 weeks Reactive gliosis and vascular proliferation around the necrotic
area.
Repair is performed by astrocytes that migrate to the area during
this time [8].
Liquefactive necrosis (1–4 weeks)
(Figure 6)
>2 weeks Glial scar formation.
As necrotic tissue is resorbed, a cystic space forms, which is then
surrounded by astrocyte and newly formed capillaries.
The enlargement and proliferation of astrocytes peripherally
around the area of necrosis forms the glial scar.
Cystic area surrounded by dense
glial fibers (>4 weeks)
(Figure 6)
Table 4. Stroke phenomenon—event, neuropathological time line.
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7. Cerebrovascular Accidents (CVAs)
7.1. Clinical signs
Sudden onset, or a step‐wise progression over hours (even days), is typical presentation. In
theory, focal signs relate to the distribution of the artery and or arteriole affected, but when
collateral supplies have the capacity to supply their territory it will cloud the issue of a pure
clinical presentation depending on the vascular territory of the vessel involved as we know its
anatomy.
Clinical presentation includes the following:
– 1° signs of vascular territory affected;
– 2° signs due to mass effect from edema formation and or brain herniation, and clinical
signs of increased ICP (Cushing syndrome), bradycardia, hypertension, and bradypnea.
7.2. Neurological and/or psychiatric new focal deficits
From all emergencies, abrupt onset of a new focal neurological deficit [9] occurs
• 95% are vascular pathologies:
◦ 85% ischemic infarcts;
◦ 15% hemorrhagic.
• 5% are nonvascular pathologies:
◦ seizure, tumors, psychogenic.
Diagram 2. Cerebrovascular accidents.
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7.3. Stroke syndrome
This is caused by inadequate perfusion of a region of CNS. Many causes but same clinic/end
results (Diagram 3) can occur.
7.4. Occlusive cerebrovascular disease
TIA (transient ischemic attack): a focal neurologic deficit that lasts ≤24 h (by definition), but in
up to 70% of cases lasts only ≤10 min [10] (Diagram 2) (Tables 5 and 6). Of patients with a
deficit persisting >60 min, only 14% will resolve with 24 h [11]. Ninety percent of patients with
TIAs will have had reversal within 4 h of onset. An ischemic deficit resolves rapidly.
Infarct types/classification
– Lacunar
– Territorial (e.g., MCA,
ACA)
– End‐zone infarcts
– Border‐zone/watershed
infarcts
– Global cerebral
hypoxia/ischemia
Major causes of stroke (Diagram 3):
– Thrombosis in situ/local
– Atherothromboembolism distant/nonlocal
– Heart emboli
• Atrial fibrillation
• Infective endocarditis
• MI
– CNS bleed
• ↑ in BP
• Trauma
• Aneurysms/AVMs
Arteries with a diameter ≥ of MCA, superior
branch of MCA included
Arteries with a diameter < of MCA
The most important risk
factors are
Atrial fibrillation – HTN (associate long‐standing HTN
with time and severity. Hence the
age effect)
– Diabetes
– Smoking
Treatment, options – r‐tPA
– Mechanical thrombectomy
– Embolectomy, surgically
– Vascular bypass
– Decompression
Therapeutic, preventive.
Table 5. Infarct types, major causes of stroke, and treatment options.
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The major clinical types of cerebrovascular diseases:
– Thrombosis (atherothrombotic)‐carotid (most common site of origin)
– Embolism‐MCA (most commonly occluded vessel)
– Hemorrhage
Vascular distribution:
– ≈50% cerebral hemisphere infarcts
– ≈25% brainstem infarcts
– ≈25% lacunar infarcts
Table 6. Major clinical types of cerebrovascular diseases and vascular distribution.
RIND (reversible ischemic neurologic deficit): a focal deficit lasting ≥24 h but less than 1 week. It
comprises only 2.5% of patients admitted with TIA, RIND, or CVA [11].
Cerebrovascular accidents: also known as stroke. A permanent (irreversible) neurologic deficit
caused by inadequate perfusion of a region of the brain or brain stem.
7.5. Common clinical problems in cerebrovascular disease
– The patient with a history of an ischemic attack or small stroke in the past;
– The patient with atrial fibrillation;
– The patient with a recent stroke that may not be complete;
– The non‐evident or misconstrued syndromes of cerebrovascular disease;
– The comatose‐stroke patient:
– The most common cause (MCC) of vascular coma is intracranial hemorrhage
• Usually deep in the hemisphere
• Less often in the
◦ Cerebellum/brainstem
◦ Extensive subarachnoid hemorrhage
◦ Basilar artery occlusion.
– Seizure following stroke
7.6. “Malignant” middle cerebral artery territory infarction
– Occurs in up to 10% of stroke patients [12];
– Mortality of up to 80% (mostly due to severe postischemic cerebral edema) [13].
7.7. Cerebellar infarction
Relatively rare, seen on up to 1% of all CTs obtained for any reason [14].
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7.8. Cardiogenic brain emboli
About one stroke in six is cardioemb [15]
• Fibrin‐rich thrombi (mural thrombi);
• Platelets (nonbacterial thrombotic endocarditis);
• Calcified material (aortic stenosis);
• Tumor particles (atrial myxoma).
7.9. Following acute myocardial infarction (MI)
– 2.5% of patients will have a CVA within 1–2 weeks, higher risk with anterior wall MI (≈6%)
versus inferior wall MI (≈1% risk).
7.10. Atrial fibrillation (A-fib)
Nonrheumatic patients with A‐fib have a three‐ to five fold increased risk of stroke [16]:
– With a 4.5% rate of stroke/year without treatment [17];
– About 75% of CVAs in patients with A‐fib are due to left atrial thrombi [18].
Independent risk factors for CVA in patients with A‐fib are as follows:
– Advanced age;
– Prior embolism (CVA or TIA);
– HTN;
– Diabetes mellitus (DM);
– Echocardiographic evidence of left atrial enlargement or left ventricular dysfunction.
Prosthetic heart valves: patients with mechanical prosthetic heart valves on long‐term anticoa‐
gulation have an embolism rate of
– 3%/year for mitral valve, and −1.5%/year for aortic valve;
– with bioprosthetic heart valves and no anticoagulation, the risk is 2–4%/year.
Paradoxical embolism can occur with a patent foramen ovale, which is present in 10–18% of the
general population, but in up to 56% of young adults with unexplained CVA [19]; for this
process to occur,
– The defect must be old enough to create a reverse of shunt (Eisenmenger syndrome);
– Or there should be moments where differences in pressure from the right side of the heart
are greater than those on the left.
A cerebrovascular event in the setting of a known venous thromboembolic disease is suspicious
for paradoxical embolism, and they can occur in patients with
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– patent foramen ovale, atrial septal defects, ventricular septal defects;
– large pulmonary arteriovenous malformations (AVMs) [20].
Lacunar strokes: They are small infarcts resulting from the occlusion of penetrating branches.
The size of infarcts ranges from 3 to 20 mm. Although their clinic might be devastating, they
are the object of prevention and/or medical treatment alone.
Diagram 3. Stroke event.
8. Diagnosis
Many centers now have strict protocols for the diagnosis and treatment of any stroke event,
and such steps should be seriously considered even when a patient presents with minimal
clinical signs because the next event might be fatal (Table 7).
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Steps to the right
path:
– Epidemiological
data
– Clinical event
– Medical history
– Medical examination
– Physical
– Instrumental
– Blood work
– Imagery
– CT
scan/angio
– Angio/
angio‐MRI/MRI 
– Doppler
– Use NIH Stroke Scale
 
Prompt investigation to confirm the diagnosis and avoid further stroke
events, but consider whether results will affect management.
Must Search for
• HTN
• Cardiac sources of emboli
• Noncardiac sources of emboli
• Carotid artery stenosis (carotid causes of stroke are the source in >30% of
patients affected, they may recur)
• Hypoglycemia, hyperglycemia
• Lipid metabolism disorders
• Vasculitis
• Infectious sources of emboli
• Coagulopathies
• Hematological diseases (most commonly)
◦ Polycythemia vera
◦ Sickle cell disease
◦ Multiple myeloma
 
Table 7. Diagnosis of stroke and tests used.
8.1. Imaging
1. Emergency imaging of the brain is recommended before initiating any specific treatment
for acute stroke [21]. In most instances, nonenhanced CT will provide the necessary
information to make decisions about emergency management.
2. If endovascular therapy is contemplated, a noninvasive intracranial vascular study is
strongly recommended during the initial imaging evaluation of the acute stroke patient
but should not delay intravenous (IV) recombinant tissue plasminogen activator (r‐tPA)
if indicated. For patients who qualify for intravenous r‐tPA according to guidelines from
professional medical societies, initiating intravenous r‐tPA before noninvasive vascular
imaging is recommended for patients who have not had noninvasive vascular imaging as
part of their initial imaging assessment for stroke. Noninvasive intracranial vascular
imaging should then be obtained as quickly as possible.
3. The benefits of additional imaging beyond CT and CTA or MR and MRA, such as CT
perfusion or diffusion‐ and perfusion‐weighted imaging, for selecting patients for
endovascular therapy are unknown. Further randomized, controlled trials may be helpful
to determine whether advanced‐imaging paradigms employing CT perfusion, CTA, and
MRI perfusion and diffusion imaging, including measures of infarct core, collateral flow
status, and penumbra, are beneficial for selecting patients for acute reperfusion therapy
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who are within 6 h of symptom onset and have an ASPECTS (Alberta Stroke Program
Early CT score).
8.1.1. CT scan
It is the emergency procedure, and we should always try to perform a non‐contrast brain CT
scan within 6 h of clinic occurrence, to help us rule out the following (Figure 7):
Figure 7. Stroke evolution followed with imagery, CT, and MRI. Non‐contrast CT scan images at hour 2 (image 1), day
2 (image 2), week 2 (image 3), and week 3 (image 4) of stroke event. Non‐contrast MRI at hour 12 of stroke event (im‐
age 5). CT scan findings in ischemic CVAs: Note: These principles do not apply to small lacunar infarcts, or hemorrhagic CVAs.
– Hemorrhage (intraparenchymal or SAH);
– Hematoma;
– Lesions (tumors, vascular).
CT scan, indicated in almost all situations of emergency, is strongly suggested in cases when
– Anticoagulation or thrombolytic therapy is indicated (first, we must rule out hemorrhage);
– ICH is suspected;
– Surgical lesions are suspected (vascular, tumoral).
First 12–24-h normal scan can be seen in between 10 and 70% of patients with MCA‐CVAs.
Early findings of imagery include the following:
1. Hyperdense artery sign (of the vessel involved, indicative of intra‐arterial (IA) clot), 12%
of patients, within 24 h of CVA, and in 23% of scans done within the first 6 h [22].
2. Focal low attenuation within the gray matter.
3. Mass effect (seen commonly from day 1 to week 4) as
a. Effacement of cerebral sulci (often this change is subtle);
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b. Midline shift (maximal effect: end of the first week, with a range between 2 and 5
days).
4. Loss of gray‐white interface.
5. Attenuation/reduction in the strength of the signal of the lentiform nucleus.
6. Hypodensity involving the insular region.
7. Enhancement, 33% of the patients. CVA becomes isodense (masking effect) or hyperdense
with normal brain, which rarely may be the only indication of the infarction.
At 48 h, most of CVAs can be seen as areas of low density.
In 1–2 weeks, we see a sharp demarcation of the CVA area.
In up to 10% of CVAs, there may be a short window, between the first and second weeks where
the CVA becomes isodense (called fogging effect). An IV contrast scan and/or an MRI will
demonstrate these.
Atrophy is usually seen by the end of the second week to the fifth.
At 3 weeks, the density of the CVA will approach that of the CSF.
Hyperdense artery sign on CT scan: This test has a low sensitivity, but a high specificity when the
most common differential diagnosis of carotid dissection, calcified atherosclerosis of vessels
(usually bilateral), or high hematocrit has been ruled out first. However, this test does not have
independent prognostic significance [23].
8.1.1.1. CT enhancement with IV contrast in CVA:
– Many will enhance by day 6;
– Most will enhance by day 10;
– Some will enhance up to 5 months;
– Enhancement of gyri is common, seen by 1 week usually, predominantly in the gray
matter. Differentiate with inflammatory infiltrating lesions due to the breakdown of
blood‐brain barrier (BBB).
– Note: there should not be enhancement at the same time as there is mass effect.
8.1.2. Magnetic resonance imaging
‐ More sensitive than CT scan, especially between hours 8 and 24, specifically for brain stem
and cerebellar CVAs.
MRI enhancement patterns [24]:
1. Intravascular enhancement, 75% of patients, may indicate areas of the brain at risk of
infarction.
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2. Meningeal enhancement, especially with dural involvement, in 35% of cortical CVAs
between days 1 and 3.
3. Transitional enhancement, two types coexist with early evidence of BBB breakdown,
usually seen on days 3−6.
4. Parenchymal enhancement classically appears as a cortical/subcortical gyral enhance‐
ment. May not be apparent for the first 1−2 days, and gradually approaches 100% by 1
week. Enhancement may eliminate “fogging effect” (as on CT scan), which may obscure
some CVAs at about 2 weeks on unenhanced T2WI.
8.1.3. Emergency cerebral angiography is used in the diagnosis of:
– Pathologies with early CVA in carotid distribution;
– If diagnosis is still questionable (e.g., aneurysms, vasculitis);
– Pathologies with rapid recovery, suggesting carotid TIA in the face of increasing stenosis.
Note: Avoid angio if the patient is
– Unstable or with severe disabling neurological deficit.
Figure 8. Emergency cerebral angiography. Cutoff sign: vessel ending abruptly at the point of the MCA occlusion.
Findings include the following:
1. Cutoff sign: vessel ends abruptly at the point of obstruction (Figure 8).
2. String sign: narrow strand of contrast in a vessel with high‐grade stenosis.
3. “Luxury perfusion”: reactive hyperemia is a recognized response of cerebral tissue to
injury (trauma, infarction, epileptogenic focus/foci). It is blood flow in excess of demand
due to the abolition of CBF autoregulation due to acidosis [25]. It shows as accelerated
circulation adjacent to the infarct with a stain or blush and early venous drainage.
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9. Stroke prevention
As a general principle to prevent primary and or secondary stroke or TIA events, we must
identify and control all modifiable risk factors and treat all comorbid diseases (Table 8).
Preventing stroke = Risk factor prevention
Preventing and treating:
– Diabetes
– HTN
– Lipid disorders
– Chronic kidney disease
– Atherosclerotic plaque formation
– Smoking
Table 8. How to prevent stroke
Patients with highest/strongest risk factors (coronary heart disease equivalent) (Diagram 3)
are at the same risk of CV events (e.g., MI, stroke) as patients with known coronary heart
disease.
Cardiovascular mortality in patients with type 2 DM increases by two to four times, of which
– 40% of patients die 2° to coronary heart disease;
– Coronary heart disease, not stroke, is the MCC of death.
In patients with type 2 DM,
– 40% die from coronary heart disease;
– 10% die from cerebrovascular accidents;
– 85% from stroke.
It will be of great pharmacological importance to study the chemical structure of thrombi, from
autopsy studies. The study of chemical structure of the local‐occluding thrombus and the
possible site of its release and their comparison as well will help
• determine their nature (chemically) and how we can treat these elements (anticlot‐drug
development or thrombolytic/clot‐lytic strategies);
• make a comparison between the locally found thrombus on the occluded vessel with the
location of its release/formation and how different they are and local tissue changes from
the site of origin with time.
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Diagram 4. Questioner of the first clinical encounter with the patient.
In a recent trial involving patients without diabetes who had insulin resistance along with a
recent history of ischemic stroke or TIA, the risk of stroke or myocardial infarction was lower
among patients who received pioglitazone than among those who received placebo. Pioglita‐
zone was also associated with a lower risk of diabetes but with higher risks of weight gain,
edema, and fracture [26]. Every clinic must have a systemic approach in preventive diseases,
steps that answer important questions for future preventive measurements (Diagram 4).
10. Treatment
Start treatment after the first event and define vascular risks—do not wait for another one, it
could be a stroke. Control risk factors for stroke and myocardial infarction, the commonest
mode of death after TIA.
Protocols, treatment modalities (Diagrams 5 and 6) are designed in their simplicity to be
applicable everywhere, although some limitations apply [5, 6]. We have to consider all
standards and suggest applications accordingly, in simple steps that can be implemented
anywhere. This is what in science we would call “Ideal.”
Treatment of atherothrombotic infarction and TIAs includes the following:
– Preventive measures
– Management of the acute phase
– Measures to restore the circulation and arrest the pathological process
– Thrombolytic agents
Cerebrovascular Anatomy, Neuropathology, Clinics of Stroke: Endovascular Treatment, Decompressive Craniectomy
http://dx.doi.org/10.5772/64610
159
– Acute surgical revascularization
– Treatment of cerebral‐infarction edema, and raised intracranial pressure
– Anticoagulation drugs
– Antiplatelet drugs
– Other forms of medical treatment
– Surgery and angioplasty for symptomatic carotid stenosis
– Asymptomatic carotid stenosis evaluation
– Physical therapy and rehabilitation.
Of these modalities, surgical and endovascular treatment are technically indicated for stroke
events caused by vascular accidents in arteries with diameter as or greater than MCA, of
anterior and or posterior circulation. Smaller‐size arteries have technical limitations in
performing any of these modalities, except for r‐tPA and in selected cases of bypass surgery
when it can help restore flow in smaller‐size arteries that are occluded (should the size allow
the technique to be performed).
We know now that thrombus formation can occur in the absence of fibrin/fibrinogen and or
vWF (von Willebrand Factor) or both, and either or both are target/s of pharmacological
treatments. This might be one of the reasons why drug/medical thrombolysis and or prophy‐
laxis were not successful for all the patients within the same risk group, giving us new
trajectories to look in and think of new and better strategies in the medical treatment of stroke
[27–31].
Diagram 5. Treatment modalities of stroke.
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Diagram 6. Treatment modality steps followed during a (stroke) vascular accident.
10.1. Therapeutic/endovascular treatment for acute ischemic stroke – current concepts:
10.1.1. Ischemic penumbra
In 1981, Astrup et al. reported a reversible non-functioning brain tissue due to ischemia which is
known as “ischemic penumbra” [32]. This ischemic but non-infarcted tissue is potentially
salvageable. Without rapid reperfusion, however, the penumbral tissue goes to cell death, that
is, infarction. As the purpose of ischemic stroke is to regain the lost neurological deficits, the
salvage of penumbral tissue is a goal of acute stroke treatment.
How is penumbra identified?
Penumbral tissue can be inferred by showing both of underperfused brain tissue within a
threshold of functional impairment and of infarction (ischemic core) [33]. The hypoperfused
brain tissue without infarction can be considered as penumbra [33].
Cerebral blood flow is measurable by a single-photon emission CT (SPECT); however,
performing SPECT is quite difficult in an emergent clinical setting. Perfusion CT and/or MRI
is rather feasible compared to SPECT, and they can provide perfusion image of the brain. MR
diffusion-weighted image (DWI) can visualize cytotoxic edema and are useful to detect
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hyperacute ischemic brain tissue. As a rule of thumb, significant underperfusioned brain tissue
with symptoms without showing abnormalities in MR diffusion‐weighted image is considered
as “ischemic penumbra” [33, 34].
10.1.2. Approval of IV r-tPA
In 1995, the efficacy of intravenous (IV) thrombolysis in patients with acute ischemic stroke
(AIS) was first reported (the National Institute of Neurological Disorders and Stroke  (NINDS)
study) [35] (Table 9). In the study, patients with AIS who were treated with IV recombinant
tissue plasminogen activator (r‐tPA) had a better prognosis compared to those without IV r‐
tPA [35]. In 1996, the next year, the US Food and Drug Administration approved the intrave‐
nous administration of rt‐PA in patients with AIS within 3 h after the onset. After that, ECASS
III reported an efficacy of IV r‐tPA within 4.5 h in 2008 [46]; IV r‐tPA is eligible for AIS patients
within 4.5 h at the present time.
Indications  Contraindications
– Acute ischemic stroke age, 18–85 [21, 38–40] 
– Onset of symptoms 3–4.5 h before r‐tPA
administration
– Stroke symptoms present for at least
30 min with no significant improvement
before treatment
– IV r‐tPA should not be withheld from
patients because of microbleeds seen on
MRI [41]
5. Severe hypertension does not need to
preclude treatment with IV r‐tPA for
patients with acute stroke, provided it can
be safely controlled with
antihypertensive medications [38, 42, 43]
Absolute:
– Acute or history of intracranial hemorrhage
(intraparenchymal, subarachnoid (even if CT scan was
normal), intraventricular hemorrhage, epidural, subdural
hematoma, hemorrhagic conversion of infarction)
– Severe uncontrolled hypertension (systolic pressure >185
mmHg or diastolic pressure >110 mmHg, or aggressive
treatment (IV medication) necessary to reduce blood pressure
to these limits)
– Serious head trauma or stroke in the previous 3 months
– Thrombocytopenia (platelet count <100,000/ml3) and
coagulopathy
– Current use of anticoagulant with international normalization
ratio (INR) >1.7 or partial thromboplastin (PT) >15 s
– Administration of heparin within the 48 h preceding the onset
of stroke, with an activated partial thromboplastin time at
presentation exceeding the upper limit of the normal range
– Low‐molecular‐weight heparin (LMWHs) within 24 h [43]
– Oral anticoagulant treatment, direct thrombin inhibitors, and
factor Xa inhibitors
– Severe hypo‐ or hyperglycemia (blood glucose <50 mg/dl or
>400 mg/dl)
– Early radiographic ischemic changes
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Indications  Contraindications
Relative
– Advanced age (older than 80 years [21, 43])
– Mild or improving stroke symptoms (symptoms rapidly
improving or only minor before start of infusion)
– Severe stroke as assessed clinically (NIHSS score of >25) or by
appropriate imaging techniques, or coma [44, 45]
– Major surgery or severe trauma within the previous 3 months
[44]
– Arterial puncture of noncompressible vessel
– Recent gastrointestinal or genitourinary hemorrhage
– Seizure at the onset of stroke
– Recent myocardial infarction
– CNS structural lesions
– Time of symptoms onset unknown
– Combination of previous stroke and diabetes mellitus
– Other major disorders associated within and increased risk
of bleeding
Table 9. Indications and contraindications for treatment with r‐tPA [36–38].
10.1.3. Drawbacks of IV r-tPA
One of the major drawbacks of IV r‐tPA is systemic hemorrhagic complication. The clinicians
should be cautious when using IV r‐tPA in patients with AIS presenting with laterality in blood
pressure of arms. Although it is very occasionally, some patients with acute aortic dissection
presents with symptoms of AIS [47]. As the clinical feature of AIS can outweigh those of aortic
dissection in an emergent clinical setting, IV r‐tPA can be administered before a diagnosis of
aortic dissection is established [47]. The number of reported cases is small; however, more than
half of AIS associated with aortic dissection are reported to be fatal [47]. As intravenously
infused r‐tPA will be delivered to anywhere in a body, hemorrhage of any organs can develop.
We experienced a case of AIS which developed fatal intraperitoneal hemorrhage following IV
r‐tPA [48]. The bleeding point was considered to be biopsied liver [48].
10.1.4. Limitation of r-tPA
After IV r‐tPA was approved, findings of recanalization rate by occlusion site have been
obtained. Recanalization rate just after IV r‐tPA varies depending on reports; however, roughly
it is reported as 10% in the internal carotid artery, 30% in the middle cerebral artery, M1, and
70% in the middle cerebral artery, M2 [49]. It is really less surprising when we consider a
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volume of a thrombus. Assuming that the diameter of the internal carotid artery is 4 mm and
those of the distal middle cerebral artery is 2 mm and a thrombus is a sphere, a ratio of the
volume of a thrombus lodging to the internal carotid artery to a thrombus lodging to the distal
middle cerebral artery becomes 8. However, a dose of IV r-tPA is determined not by a size of
thrombus but by a patient’s body weight.
To overcome the drawbacks of IV r-tPA, a concept of additional neurointervention for patients
who are refractory or not eligible to IV r-tPA has emerged. In 2004, the Interventional Man-
agement of Stroke (IMS) study investigators reported the feasibility and safety of a combination
therapy (IV r-tPA alone vs. IV r-tPA plus intra-arterial (IA) administration of r-tPA) [50]. IMS-3,
a final version of bridging study conducted by IMS study investigators, failed to show any
benefits of additional neurointervention following IV r-tPA [51]. However, in 2015, another
five randomized controlled trials succeeded in showing the effectiveness of the additional
neurointervention [52–56].
10.1.5. Illustrative case
A 75-year-old man suddenly developed right hemiplegia and total aphasia. On examination,
his National Institutes of Health Stroke Scale (NIHSS) score was 20. About 4.5 h had already
past when he arrived at our hospital, and IV r-tPA was not eligible. Diffusion-weighted MR
image showed a moderate ischemic change of the left middle cerebral artery (Figure 9);
however, it was difficult to explain all of his neurological symptoms by the ischemic change.
Neurointervention was performed, and a complete recanalization was obtained by a stent
retriever (Figure 10). Improvement of his neurological deficits was obtained. The complete
recovery of the right hemiplegia was obtained, and he was discharged with mRS2.
Figure 9. Diffusion-weighted MR image (a, b) and FLAIR image (c, d) on admission. Acute ischemia was noted in the
left middle cerebral artery on diffusion-weighted MR image (a, b); however, no lesions were detected on FLAIR image
(c, d), suggesting hyperacute ischemia.
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Figure 10. Lateral view of the left carotid angiogram before the neuroendovascular procedure (a). Microcatheter injec‐
tion confirmed that a tip of the microcatheter was in distal to a thrombus (b). Solitaire FR 6 × 30 mm was deployed, and
the Solitaire was pulled with a proximal flow control (c). After one passage of the Solitaire FR, a complete recanaliza‐
tion was obtained (d).
10.1.6. Future issues
Twenty years has been passed since the publication of NINDS study. It is quite evident that r‐
tPA is effective in patients with AIS within 4.5 h. It is and will be impossible to conduct
randomized controlled trial comparing neurointervention and medical management without
r‐tPA in patients with AIS within 4.5 h. Thus, further issues to be addressed should be the
methodology of how to recanalize occluded vessels in conjunction with IV r‐tPA. Should we
puncture a femoral artery during IV r‐tPA? Which devices are most suitable to recanalize? Are
there any necessary to choose devices depending on an occlusion site or nature? The next
decade will answer these questions, we believe.
A recent trial involving predominantly an Asian patient with acute ischemic stroke did not
show the noninferiority of low‐dose alteplase to standard‐dose alteplase with respect to death
and disability at 90 days. There were significantly fewer symptomatic intracerebral hemor‐
rhages with low‐dose alteplase [57].
Although the INR and pTT are not adequately reliable indicators of the anticoagulation effect
of direct thrombin inhibitors (dabigatran), the thrombin time (TT) is sensitive to the presence
of dabigatran activity. Based on the current understanding of pharmacokinetics, IV r‐tPA may
be considered reasonable in some cases if patients have normal TT, aPTT, and PT, but this
should be a subject of future research [38, 58].
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10.1.7. The guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding
Endovascular Treatment, Endovascular Interventions:
1. Patients eligible for intravenous r‐tPA should receive intravenous r‐tPA even if endovas‐
cular treatments are being considered (Class I; Level of Evidence A) [21, 59].
2. Patients should receive endovascular therapy with a stent retriever if they meet all the
following criteria (Class I; Level of Evidence A):
a. prestroke mRS scores 0–1,
b. acute ischemic stroke receiving intravenous r‐tPA within 4.5 h of onset according to
guidelines from professional medical societies,
c. causative occlusion of the internal carotid artery or proximal MCA (M1),
d. age ≥18 years,
e. NIHSS score of ≥6,
f. ASPECTS of ≥6, and
g. treatment can be initiated (groin puncture) within 6 h of symptom onset.
3. As with intravenous r‐tPA, reduced time from symptom onset to reperfusion with
endovascular therapies is highly associated with better clinical outcomes. To ensure
benefit, reperfusion to TICI grade 2b/3 should be achieved as early as possible and within
6 h of stroke onset (Class I; Level of Evidence B‐R).
4. When treatment is initiated beyond 6 h from symptom onset, the effectiveness of endo‐
vascular therapy is uncertain for patients with acute ischemic stroke who have causative
occlusion of the internal carotid artery or proximal MCA (M1) (Class IIb; Level of Evidence
C).
5. In carefully selected patients with anterior circulation occlusion who have contraindica‐
tions to intravenous r‐tPA, endovascular therapy with stent retrievers completed within
6 h of stroke onset is reasonable (Class IIa; Level of Evidence C). There are inadequate
data available at this time to determine the clinical efficacy of endovascular therapy with
stent retrievers for those patients whose contraindications are time‐based or nontime‐
based (e.g., prior stroke, serious head trauma, hemorrhagic coagulopathy, or receiving
anticoagulant medications).
6. Although the benefits are uncertain, the use of endovascular therapy with stent retrievers
may be reasonable for carefully selected patients with acute ischemic stroke in whom
treatment can be initiated (groin puncture) within 6 h of symptom onset and who have
causative occlusion of the M2 or M3 portion of the MCAs, anterior cerebral arteries,
vertebral arteries, basilar artery, or posterior cerebral arteries (Class IIb; Level of Evidence
C).
7. Endovascular therapy with stent retrievers may be reasonable for some patients <18 years
of age with acute ischemic stroke who have demonstrated large vessel occlusion in whom
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treatment can be initiated (groin puncture) within 6 h of symptom onset, but the benefits
are not established in this age group (Class IIb; Level of Evidence C).
8. Although the benefits are uncertain, the use of endovascular therapy with stent retrievers
may be reasonable for patients with acute ischemic stroke in whom treatment can be
initiated (groin puncture) within 6 h of symptom onset and who have prestroke mRS score
of >1, ASPECTS.
9. Observing patients after intravenous r‐tPA to assess for clinical response before pursuing
endovascular therapy is not required to achieve beneficial outcomes and is not recom‐
mended (Class III; Level of Evidence B‐R).
10. The use of stent retrievers is indicated in preference to the MERCI device (Class I; Level
of Evidence A). The use of mechanical thrombectomy devices other than stent retrievers
may be reasonable in some circumstances (Class IIb, Level B‐NR).
11. The use of proximal balloon‐guide catheter or a large bore distal access catheter rather
than a cervical guide catheter alone in conjunction with stent retrievers may be beneficial
(Class IIa; Level of Evidence C). Future studies should examine which systems provide
the highest recanalization rates with the lowest risk for nontarget embolization.
12. The technical goal of the thrombectomy procedure should be a TICI 2b/3 angiographic
result to maximize the probability of a good functional clinical outcome (Class I; Level of
Evidence A). The use of salvage technical adjuncts including intra‐arterial fibrinolysis may
be reasonable to achieve these angiographic results, if completed within 6 h of symptom
onset (Class IIb; Level of Evidence B‐R).
13. Angioplasty and stenting of proximal cervical atherosclerotic stenosis or complete
occlusion at the time of thrombectomy may be considered but the usefulness is unknown
(Class IIb; Level of Evidence C). Future randomized studies are needed.
14. Initial treatment with intra‐arterial fibrinolysis is beneficial for carefully selected patients
with major ischemic strokes of <6‐h duration caused by occlusions of the MCA (Class I;
Level of Evidence B‐R). However, these data derive from clinical trials that no longer
reflect current practice, including the use of fibrinolytic drugs that are not available. A
clinically beneficial dose of intra‐arterial r‐tPA is not established, and r‐tPA does not have
FDA approval for intra‐arterial use. As a consequence, endovascular therapy with stent
retrievers is recommended over intra‐arterial fibrinolysis as first‐line therapy (Class I;
Level of Evidence E).
15. Intra‐arterial fibrinolysis initiated within 6 h of stroke onset in carefully selected patients
who have contraindications to the use of intravenous r‐tPA might be considered, but the
consequences are unknown (Class IIb; Level of Evidence C).
16. It might be reasonable to favor conscious sedation over general anesthesia during
endovascular therapy for acute ischemic stroke. However, the ultimate selection of
anesthetic technique during endovascular therapy for acute ischemic stroke should be
individualized based on patient risk factors, tolerance of the procedure, and other clinical
characteristics. Randomized trial data are needed (Class IIb; Level of Evidence C).
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General anesthesia with intubation and conscious sedation are the two most frequently used
anesthetic approaches for patients with an acute ischemic stroke receiving endovascular
therapy.
An expert consensus statement of the Society of Neurointerventional Surgery and the Neuro‐
critical Care Society recommends the use of general anesthesia for patients with severe
agitation, low level of consciousness (the Glasgow Coma Scale (GCS) of <8), loss of airway
protective reflexes, respiratory compromise, and in selected posterior circulation stroke
presenting with these features [60].
10.1.8. Patient selection
• Intracranial vessel occlusion must be diagnosed with noninvasive imaging whenever
possible before considering treatment with mechanical thrombectomy (Grade A, Level 1a,
KSU Grade A) [59].
• If vessel imaging is not available at baseline, an NIHSS score of ≥9 within 3 h, and ≥7 points
within 6 h may indicate the presence of large vessel occlusion (Grade B, Level 2a, KSU Grade
B).
• Patients with radiological signs of large infarcts (e.g., using the ASPECTS score) may be
unsuitable for thrombectomy (Grade B, Level 2a, KSU Grade B).
• Imaging techniques for determining infarct and penumbra sizes can be used for patient
selection and correlate with functional outcome after mechanical thrombectomy (Grade B,
Level 1b, KSU Grade B).
• High age alone is not a reason to withhold mechanical thrombectomy as an adjunctive
treatment (Grade A, Level 1a, KSU Grade A).
10.2. Surgical treatment
10.2.1. Embolectomy and extracranial – intracranial (EC/IC) bypass; STA – MCA bypass is this the
solution or a treatment – procedure?
Surgical embolectomy in conjunction with ligation of the cervical ICA followed by STA‐MCA
bypass might be a safe alternative method to endovascular recanalization, when the cervical
dissection of ICA is extensive and when huge secondary emboli are present along the MCA
when it is clinically indicated and or in centers that do not have a 24‐h endovascular service
[61]. In these centers, microsurgery is recommended as a first‐line treatment, after exclusion
of malignant profile based on MRI findings (i.e., minimal DWI lesion less than one‐third of the
entire MCA region despite large ICA/MCA occlusion on MRA) [5, 6, 62–64]. Spontaneous
dissection of the internal carotid artery (ICA) is one of the main causes of ischemic stroke in
young‐ to middle‐aged patients. It can cause malignant brain infarction [65], and in addition
tandem ICA and MCA occlusion independently predict poor outcomes in response to
intravenous r‐tPA [66–68]. We know that theoretically stent deployment for cervical ICA
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dissection could cause distal migration of secondary emboli, vessel laceration, and in‐stent
thrombosis [64, 69]. When other criteria are not meet, surgical embolectomy is recommended.
CBF increases significantly after bypass, and flow reservation improves significantly. Patients
with TIA experience less or no recurrence of such episodes after bypass and the neurologic
deficit remains unchanged in patients with complete stroke after bypass, with a very high
satisfaction rate after surgery as assessed by the patients themselves, in comparison to the
conservative treatment [70].
10.2.2. Bypass may be indicated and may be helpful in restoring CBF and reducing the risk of stroke in:
– Atherosclerotic plaque non treatable by endovascular or other means;
– Failure of medications to control TIA symptoms or stroke;
– Imagery (angio, CTA, and MRA) showing intra‐ and or extracranial arterial stenosis/
occlusion;
– CBF studies (CT perfusion, positron emission tomography (PET), and SPECT) show
insufficient blood flow due to arterial stenosis [5, 64, 68‐70]..
Bypass surgery might improve CBF, but it does not cure (with some exceptions) the underlying
disease.
Outside Inside
Frontal sinus, 1‐cm superior Superior
sagittal sinus
Sagittal suture, 1‐cm lateral Transverse
sinus
Lambda and lambdoid suture 1‐cm superior
Asterion and pterion
With an extensive craniectomy, we can remove an area of bone≈60 cm2.
At this range, the volume calculated to protrude through the opening will be a minimum of 60 ml.
This technique has a greater decompression effect on frontal, precentral, superior cerebral, and parietal
veins, with the greatest effects expected on the superior sagittal sinus and the confluence of sinuses.
Sixty milliliter is the maximal volume of compensation before clinical signs of herniation appear
during stroke event.
Table 10. Craniectomy landmarks to consider.
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10.3. Decompressive craniectomy (DC)
10.3.1. Age is not the limit! DC is nor the solution, nor the cure! Hemicraniectomy for malignant MCA
territory infarction
Treatment modalities for stroke has progressed and substantially changed from what we knew
two decades ago; we have now the possibility to use noninvasive treatment options and/or a
combination with surgical techniques as well. Although none of the surgical techniques is the
first to be considered, they are absolutely the last options we can use to treat stroke event and
complications (Table 11) (Diagram 6).
Indications Contraindications
Failure of r‐tPA and or endovascular treatment Prestroke mRS score of ≥2
Failure of bypass Prestroke score Barthel Index of <95
Refractory increase in ICP despite treatment (Graphic 3) GCS of <8
Brain stem involvement and or signs of herniation
Brain stem not involved and before signs of herniation Hemorrhagic transformation of the infarct
Disease affecting ICA, and or MCA, M1, M2, or either of the last in
combination with ACA or PCA (rare occurrence) ipsilateral
Related disease/conditions affecting outcome.
Coagulopathy/systemic‐blooding disorders.
Table 11. Hemicraniectomy indications and contraindications in brain malignant infarction.
Graphic 3. Volume‐pressure changes, graphic.
It may reduce mortality to as low as 32% in nondominant hemisphere CVAs [71], and it can
reduce mortality up to 37% in all corners, with surprising clinical results. Better results occur
with early surgery, before any changes associated with herniation occur [72], but it does not
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treat the underlying cause/s of the edema formation (being it transudate or exudate). It is a
very important treatment procedure that must be considered. As decompression has never
been the first treatment modality, it has mostly been considered the last and in many clinical
situations the first as well.
10.3.2. Surgical techniques and notes
Preferred skin incisions for a large decompressive craniectomy (Table 8, Figure 11) are as
follows:
Figure 11. Images 1 and 2 identify the major intracranial surgical landmarks to be considered.
– Question mark extended;
– U shape extended.
Both incisions expose the scalp greatly, with its borders along the anastomotic segments. U‐
shape incision traumatizes the vascular supply to a lesser degree [73]. However, due to the
extensive vascular collateral circulation in the scalp area, scalp necrosis is uncommon.
Figure 12. Surgical landmarks and area measurements [74, 75].
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Craniectomy landmarks and indications are listed in Tables 10 and 11 (Figure 12).
A larger craniectomy does not always mean better; however, a smaller craniectomy (the lower
threshold of 12 cm for hemicraniectomy and decompression to the temporal base) is effective
in relieving ICP. The size should always consider the risk of complications, including the
parenchymal shear stress and hemorrhage [74, 75] (Figure 12).
Age should not be the limit (each disease categories), for medical and or surgical modality
treatment decisions, but the existing and past medical conditions of the patient. By contrast,
we should push the limit and provide support for longer life expectancy with a better quality
for stroke‐related diseases [76] (Table 11).
Hemicraniectomy is increasingly used as treatment option in stroke and in head trauma, but
little is known on the physiological regional effects of hemicraniectomy in the normal brain.
In their work, Schaller et al. [77] measured in consecutive hours regional CBF, CMR of O₂, and
glucose from the brain tissue underneath the craniectomy (hemicraniectomy) of the animals
used in the study. They demonstrated for the first time that decompressive hemicraniectomy
decreases CBF, and to a lesser extent CMR of O₂ and glucose 2 h after hemicraniectomy in the
normal brain tissues that last for at least 1 day. The underlying basis of these phenomena is
not fully understood; however, their findings implied that persisting pathophysiological
processes are induced by hemicraniectomy and should be taken into consideration for surgical
indications [77].
We can use clinical findings and imagery, and analyze volumetric changes before neuronal
injury and predict which patients may benefit from hemicraniectomy. It is a life‐saving surgery
when performed correctly; it can reduce disability and mortality and improve functional
outcome as proved in several controlled trials [75, 78].
10.3.3. Dural incisions and duraplasty
– Cross, extended (Figure 13 f) or standard (Figure 13 d, e) [73, 79]. These incisions create
two smaller triangles superiorly (one and two) (Figure 13 d, e), thus creating the possibility
for a better supply from the anastomotic vessels opposite. If the axial plane of the dural
incision creates equal half’s 1–2 and 3–4), the area requiring blood supply from the
anastomotic branches (one and two) will be greater than what the vasculature can supply,
and this might create the risk of necrosis at the distal margins of each incision.
– “Maple leaf” (Figure 13 a–c): the incisions in this technique follow parallel with the
vasculature of the major branches of the middle meningeal artery supplying the dura, and
respect their segments of anastomosis. At the same time, the wide opening of the dural
leafs exposes the brain‐herniating tissue to a lesser pressure.
Standard duraplasty can be performed at the end of the decompression procedure, with a loose
graft.
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10.3.4. When should we put the bone back?
With the patient in stable clinical conditions, we should prepare to put the bone back any time
after gliosis starts forming (≥4 weeks). Although ICP helps to set a baseline of when we should
decide to put the bone back (Graphic 3), it is pathologically correct to do so during gliosis and
scar formation (Table 4), usually >2 weeks when glial scar starts to form, and best after the
fourth week when cystic area is surrounded by dense glial fibers.
Figure 13. Dural incision’s techniques.
10.3.5. Suturing of the skin (at the end of the surgery/craniectomy)
The most productive results are with a continuous suture, if a second surgical procedure will
be required; this technique allows you to remove the suture with only two cuts, and pull.
10.4. Possible modality treatments of the future
In the last couple of years, the use of transcranial ultrasound has been modified for therapeutic
use as well [80]. Its promising results will open doors for application in thrombus destruction
during the ischemic event. Its use in trans‐BBB (Blood Brain Barrier) delivery of medical
therapy has been published now, as well as its use in functional neurosurgery. This is a novel
technique, noninvasive that is starting to take shape beyond its initial plan of application and
is promising.
We recommend the use of Diagram 6 that indicates in a step‐wise manner all possible treatment
modalities we can chose based on clinical and imagery indications.
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